Abstract
Aim of the study was to evaluate efficacy and tolerability of lacosamide (LCM) as add-on in brain tumor-related epilepsy (BTRE). We followed 14 patients suffering from BTRE who had already been treated with other AEDs and who had had not experienced adequate seizure control. Eleven patients underwent chemotherapy while being treated with LCM. Mean duration of follow up was 5.4 months (min
Translated title of the contribution | Add-on lacosamide in brain tumor-related epilepsy. Preliminary report: Efficacy and tolerability |
---|---|
Original language | Italian |
Pages (from-to) | 195-197 |
Number of pages | 3 |
Journal | Bollettino - Lega Italiana contro l'Epilessia |
Issue number | 144 |
Publication status | Published - May 2012 |
ASJC Scopus subject areas
- Clinical Neurology